{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T22:22:18Z","timestamp":1787178138962,"version":"build-2736575974"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,18]]},"DOI":"10.7759\/cureus.69687","type":"journal-article","created":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T06:51:41Z","timestamp":1726728701000},"source":"Crossref","is-referenced-by-count":1,"title":["A Systematic Review of Gut Microbiota Diversity: A Key Player in the Management and Prevention of Diabetes Mellitus"],"prefix":"10.7759","author":[{"given":"Hema Manvi","family":"Koneru","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hooria","family":"Sarwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkata Varshitha","family":"Bandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohit","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pakeeza","family":"Tarar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafik","family":"Bishara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iana","family":"Malasevskaia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"What is diabetes?. (2023). Accessed. July 23, 2024: https:\/\/www.niddk.nih.gov\/health-information\/diabetes\/overview\/what-is-diabetes."},{"key":"ref2","unstructured":"Diabetes. (2023). Accessed. July 23, 2024: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/diabetes."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/5110276","article-title":"Gut microbiota and type 2 diabetes mellitus: association, mechanism, and translational applications","volume":"2021","author":"Zhang L","year":"2021","unstructured":"Zhang L, Chu J, Hao W, et al.. Gut microbiota and type 2 diabetes mellitus: association, mechanism, and translational applications. Mediators Inflamm. 2021, 2021:5110276. 10.1155\/2021\/5110276","journal-title":"Mediators Inflamm"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-321643","article-title":"Metagenomics analysis of gut microbiota in response to diet intervention and gestational diabetes in overweight and obese women: a randomised, double-blind, placebo-controlled clinical trial","volume":"70","author":"Mokkala K","year":"2021","unstructured":"Mokkala K, Paulin N, Houttu N, et al.. Metagenomics analysis of gut microbiota in response to diet intervention and gestational diabetes in overweight and obese women: a randomised, double-blind, placebo-controlled clinical trial. Gut. 2021, 70:309-18. 10.1136\/gutjnl-2020-321643","journal-title":"Gut"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2023.1255059","article-title":"The causal relationship between gut microbiota and type 2 diabetes: a two-sample Mendelian randomized study","volume":"11","author":"Sun K","year":"2023","unstructured":"Sun K, Gao Y, Wu H, Huang X. The causal relationship between gut microbiota and type 2 diabetes: a two-sample Mendelian randomized study. Front Public Health. 2023, 11:1255059. 10.3389\/fpubh.2023.1255059","journal-title":"Front Public Health"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-322630","article-title":"Faecal microbiota transplantation halts progression of human new-onset type 1 diabetes in a randomised controlled trial","volume":"70","author":"de Groot P","year":"2021","unstructured":"de Groot P, Nikolic T, Pellegrini S, et al.. Faecal microbiota transplantation halts progression of human new-onset type 1 diabetes in a randomised controlled trial. Gut. 2021, 70:92-105. 10.1136\/gutjnl-2020-322630","journal-title":"Gut"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan-a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani M","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016, 5:210. 10.1186\/s13643-016-0384-4","journal-title":"Syst Rev"},{"key":"ref9","unstructured":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. (2021). Accessed. July 23, 2024: https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne JA","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, et al.. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016, 355:i4919. 10.1136\/bmj.i4919","journal-title":"BMJ"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.1089991","article-title":"Fecal microbiota transplantation reverses insulin resistance in type 2 diabetes: a randomized, controlled, prospective study","volume":"12","author":"Wu Z","year":"2022","unstructured":"Wu Z, Zhang B, Chen F, et al.. Fecal microbiota transplantation reverses insulin resistance in type 2 diabetes: a randomized, controlled, prospective study. Front Cell Infect Microbiol. 2022, 12:1089991. 10.3389\/fcimb.2022.1089991","journal-title":"Front Cell Infect Microbiol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18414-8","article-title":"Gut microbiome-related effects of berberine and probiotics on type 2 diabetes (the PREMOTE study)","volume":"11","author":"Zhang Y","year":"2020","unstructured":"Zhang Y, Gu Y, Ren H, et al.. Gut microbiome-related effects of berberine and probiotics on type 2 diabetes (the PREMOTE study). Nat Commun. 2020, 11:5015. 10.1038\/s41467-020-18414-8","journal-title":"Nat Commun"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3390\/nu12072041","article-title":"Targeting the intestinal microbiota to prevent type 2 diabetes and enhance the effect of metformin on glycaemia: a randomised controlled pilot study","volume":"12","author":"Palacios T","year":"2020","unstructured":"Palacios T, Vitetta L, Coulson S, et al.. Targeting the intestinal microbiota to prevent type 2 diabetes and enhance the effect of metformin on glycaemia: a randomised controlled pilot study. Nutrients. 2020, 12:2041. 10.3390\/nu12072041","journal-title":"Nutrients"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.754401","article-title":"Adjuvant probiotics of Lactobacillus salivarius subsp. salicinius AP-32, L. johnsonii MH-68, and Bifidobacterium animalis subsp. lactis CP-9 attenuate glycemic Levels and inflammatory cytokines in patients with type 1 diabetes mellitus","volume":"13","author":"Wang CH","year":"2022","unstructured":"Wang CH, Yen HR, Lu WL, et al.. Adjuvant probiotics of Lactobacillus salivarius subsp. salicinius AP-32, L. johnsonii MH-68, and Bifidobacterium animalis subsp. lactis CP-9 attenuate glycemic Levels and inflammatory cytokines in patients with type 1 diabetes mellitus. Front Endocrinol (Lausanne). 2022, 13:754401. 10.3389\/fendo.2022.754401","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2018.08.008","article-title":"The effect of probiotic supplementation on glycemic control and lipid profile in patients with type 2 diabetes: a randomized placebo controlled trial","volume":"13","author":"Razmpoosh E","year":"2019","unstructured":"Razmpoosh E, Javadi A, Ejtahed HS, Mirmiran P, Javadi M, Yousefinejad A. The effect of probiotic supplementation on glycemic control and lipid profile in patients with type 2 diabetes: a randomized placebo controlled trial. Diabetes Metab Syndr. 2019, 13:175-82. 10.1016\/j.dsx.2018.08.008","journal-title":"Diabetes Metab Syndr"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12861","article-title":"Metabolic effects of Lactobacillus reuteri DSM 17938 in people with type 2 diabetes: a randomized controlled trial","volume":"19","author":"Mobini R","year":"2017","unstructured":"Mobini R, Tremaroli V, St\u00e5hlman M, et al.. Metabolic effects of Lactobacillus reuteri DSM 17938 in people with type 2 diabetes: a randomized controlled trial. Diabetes Obes Metab. 2017, 19:579-89. 10.1111\/dom.12861","journal-title":"Diabetes Obes Metab"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1177\/1932296815577425","article-title":"Addition of a gastrointestinal microbiome modulator to metformin improves metformin tolerance and fasting glucose levels","volume":"9","author":"Burton JH","year":"2015","unstructured":"Burton JH, Johnson M, Johnson J, Hsia DS, Greenway FL, Heiman ML. Addition of a gastrointestinal microbiome modulator to metformin improves metformin tolerance and fasting glucose levels. J Diabetes Sci Technol. 2015, 9:808-14. 10.1177\/1932296815577425","journal-title":"J Diabetes Sci Technol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac210","article-title":"Cardiovascular benefits of empagliflozin are associated with gut microbiota and plasma metabolites in type 2 diabetes","volume":"107","author":"Deng X","year":"2022","unstructured":"Deng X, Zhang C, Wang P, et al.. Cardiovascular benefits of empagliflozin are associated with gut microbiota and plasma metabolites in type 2 diabetes. J Clin Endocrinol Metab. 2022, 107:1888-96. 10.1210\/clinem\/dgac210","journal-title":"J Clin Endocrinol Metab"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1126\/science.aao5774","article-title":"Gut bacteria selectively promoted by dietary fibers alleviate type 2 diabetes","volume":"359","author":"Zhao L","year":"2018","unstructured":"Zhao L, Zhang F, Ding X, et al.. Gut bacteria selectively promoted by dietary fibers alleviate type 2 diabetes. Science. 2018, 359:1151-6. 10.1126\/science.aao5774","journal-title":"Science"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-05127-9","article-title":"Health improvements of type 2 diabetic patients through diet and diet plus fecal microbiota transplantation","volume":"12","author":"Su L","year":"2022","unstructured":"Su L, Hong Z, Zhou T, et al.. Health improvements of type 2 diabetic patients through diet and diet plus fecal microbiota transplantation. Sci Rep. 2022, 12:1152. 10.1038\/s41598-022-05127-9","journal-title":"Sci Rep"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.5114\/pedm.2023.132025","article-title":"The effect of oral probiotics on glycated haemoglobin levels in children with type 1 diabetes mellitus -\u00a0a\u00a0randomized clinical trial","volume":"29","author":"Shabani-Mirzaee H","year":"2023","unstructured":"Shabani-Mirzaee H, Haghshenas Z, Malekiantaghi A, Vigeh M, Mahdavi F, Eftekhari K. The effect of oral probiotics on glycated haemoglobin levels in children with type 1 diabetes mellitus -\u00a0a\u00a0randomized clinical trial. Pediatr Endocrinol Diabetes Metab. 2023, 29:128-33. 10.5114\/pedm.2023.132025","journal-title":"Pediatr Endocrinol Diabetes Metab"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmhg.2012.10.003","article-title":"Role of intestinal microflora (Lactobacillus acidophilus) in phagocytic function of leukocytes in type 2 diabetic patients","volume":"14","author":"Abo Ali FH","year":"2013","unstructured":"Abo Ali FH, Ashour ZA, Shahin RY, Zaki WK, Ragab SB, Attia MY. Role of intestinal microflora (Lactobacillus acidophilus) in phagocytic function of leukocytes in type 2 diabetic patients. Egypt J Med Hum Genet. 2013, 14:95-101. 10.1016\/j.ejmhg.2012.10.003","journal-title":"Egypt J Med Hum Genet"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aau8125","article-title":"Association of HLA-dependent islet autoimmunity with systemic antibody responses to intestinal commensal bacteria in children","volume":"4","author":"Paun A","year":"2019","unstructured":"Paun A, Yau C, Meshkibaf S, et al.. Association of HLA-dependent islet autoimmunity with systemic antibody responses to intestinal commensal bacteria in children. Sci Immunol. 2019, 4:8125. 10.1126\/sciimmunol.aau8125","journal-title":"Sci Immunol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-019-4848-7","article-title":"Metformin-induced changes of the gut microbiota in healthy young men: results of a non-blinded, one-armed intervention study","volume":"62","author":"Bryrup T","year":"2019","unstructured":"Bryrup T, Thomsen CW, Kern T, et al.. Metformin-induced changes of the gut microbiota in healthy young men: results of a non-blinded, one-armed intervention study. Diabetologia. 2019, 62:1024-35. 10.1007\/s00125-019-4848-7","journal-title":"Diabetologia"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.108985","article-title":"Changes in the gut microbiome influence the hypoglycemic effect of metformin through the altered metabolism of branched-chain and nonessential amino acids","volume":"178","author":"Lee Y","year":"2021","unstructured":"Lee Y, Kim AH, Kim E, et al.. Changes in the gut microbiome influence the hypoglycemic effect of metformin through the altered metabolism of branched-chain and nonessential amino acids. Diabetes Res Clin Pract. 2021, 178:108985. 10.1016\/j.diabres.2021.108985","journal-title":"Diabetes Res Clin Pract"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/292476-a-systematic-review-of-gut-microbiota-diversity-a-key-player-in-the-management-and-prevention-of-diabetes-mellitus","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T06:51:44Z","timestamp":1726728704000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/292476-a-systematic-review-of-gut-microbiota-diversity-a-key-player-in-the-management-and-prevention-of-diabetes-mellitus"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,18]]},"references-count":26,"URL":"https:\/\/doi.org\/10.7759\/cureus.69687","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9,18]]}}}